Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer.

Molecular bioSystems - 26 Apr 2016

Wang Debby D, Lee Victor H F, Zhu Guangyu, Zou Bin, Ma Lichun, Yan Hong

Abstract excerpt

EGFR-mutated non-small-cell lung cancer (NSCLC) has long been a research focus in lung cancer studies. Besides reversible tyrosine kinase inhibitors (TKIs), new-generation irreversible inhibitors, such as afatinib, embark on playing an important role in NSCLC treatment. To achieve an optimal application of these inhibitors, the correlation between the EGFR mutation status and the potency of such an inhibitor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Molecular Conformation

Share to Molecular Structure

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 26961138
DOI: 10.1039/c6mb00038j

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer.PMID 26961138Read ↗

Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer.Semantic proximity Read ↗

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings.Semantic proximity Read ↗

Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.Semantic proximity Read ↗

Afatinib for the treatment of advanced non-small-cell lung cancer.Semantic proximity Read ↗

Afatinib for the first-line treatment of EGFR mutation-positive NSCLC in China: a review of clinical data.Semantic proximity Read ↗

Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.Semantic proximity Read ↗

First-Line Afatinib plus Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study.Semantic proximity Read ↗

Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review.Semantic proximity Read ↗

Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study.Semantic proximity Read ↗

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib.Semantic proximity Read ↗

Real-world outcomes of first- and second-generation tyrosine kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: A retrospective observational cohort study.Semantic proximity Read ↗

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.